Prognostic role of circulating exosomal miRNAs in multiple myeloma

Blood

Volumn 129, Issue 17, 2017, Pages 2429-2436

  Manier, Salomon ^a,b,c   Liu, Chia Jen ^a,d,e   Avet Loiseau, Hervé ^f   Park, Jihye ^a   Shi, Jiantao ^a   Campigotto, Federico ^a   Salem, Karma Z ^a   Huynh, Daisy ^a   Glavey, Siobhan V ^a   Rivotto, Bradley ^a   Sacco, Antonio ^a,g   Roccaro, Aldo M ^a,g   Bouyssou, Juliette ^a   Minvielle, Stéphane ^h   Moreau, Philippe ⁱ   Facon, Thierry ^b   Leleu, Xavier ^j   Weller, Edie ^f   Trippa, Lorenzo ^f   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g SPEDALI CIVILI   (Italy)

^h CNRS   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j POITIERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LET 7B PROTEIN; MELPHALAN; MICRORNA; MICRORNA 18A; RNA; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN18A MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; EXOSOME; FEMALE; HUMAN; HUMAN CELL; INTERNATIONAL STAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SERUM; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; AUTOTRANSPLANTATION; BLOOD; CASE CONTROL STUDY; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KARYOTYPING; METABOLISM; MORTALITY; PROGNOSIS; SEQUENCE ANALYSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BORTEZOMIB; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DEXAMETHASONE; EXOSOMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; MALE; MELPHALAN; MICRORNAS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 85018902695     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-742296     Document Type: Article

References (40)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
2. Chng WJ, Dispenzieri A, Chim CS, et al; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-277.
3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005;23(25): 6281]. J Clin Oncol. 2005;23(15):3412-3420.
4. Avet-Loiseau H, Durie BG, Cavo M, et al; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27(3):711-717.
5. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
6. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-579.
7. Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883-891.
8. Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123(4):1542-1555.
9. Melo SA, Sugimoto H, O'Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707-721.
10. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597-610.
11. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
12. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105(35):12885-12890.
13. Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24(3):629-637.
14. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-1801.
15. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189-198.
16. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48-57.
17. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11(2):136-146.
18. Liu N, Chen NY, Cui RX, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633-641.
19. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids: the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467-477.
20. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
21. Taylor DD, Zacharias W, Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol Biol. 2011;728:235-246.
22. Kodani M, Yang G, Conklin LM, et al. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol. 2011;49(6):2175-2182.
23. D'haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol Biol. 2012;822:261-272.
24. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145-156.
25. Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99(3):511-518.
26. Hao M, Zang M, Wendlandt E, et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015;136(8):1835-1844.
27. Rocci A, Hofmeister CC, Geyer S, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014;28(9):1922-1926.
28. Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67(1):33-41.
29. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-182.
30. Xiang M, Zeng Y, Yang R, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 2014;454(1):210-214.
31. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009;10(6):R64.
32. Cui W, Ma J, Wang Y, Biswal S. Plasma miRNA as biomarkers for assessment of total-body radiation exposure dosimetry. PLoS One. 2011;6(8):e22988.
33. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18(10):505-516.
34. Manier S, Powers JT, Sacco A, et al. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma [published online ahead of print 11 November 2016]. Leukemia. doi:10.1038/leu.2016.296.
35. Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41(7):843-848.
36. Jacobsen A, Silber J, Harinath G, Huse JT, Schultz N, Sander C. Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol. 2013;20(11):1325-1332.
37. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in cancer. Cell. 2009;137(3):586-586.e1.
38. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133(2):217-222.
39. Krutilina R, Sun W, Sethuraman A, et al. MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res. 2014;16(4):R78.
40. Teng Y, Mu J, Hu X, et al. Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget. 2016;7(18):25683-25697.